Cell line · CVCL_1218
Papers129
1 to 20 of 129
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Regulation of the lncRNA NEAT1 by p53-ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor-Resistant Head and Neck Squamous Cell Carcinoma. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SLC15A4 promotes oral cancer progression by regulating TLR9 and activating the JAK/STAT signaling pathway. | Head Face Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ZBP1 Drives CD8+ T cell-mediated anti-tumor immunity in head and neck squamous cell carcinoma. | PLoS Genet | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TRAPPC4 Promotes GPX4 Stability to Drive Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia Induces a Mitotic Survival Advantage After Radiotherapy in Head and Neck Cancer Cells. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CCL26-Mediated Modulation of Endothelial Secretome by Hypoxia-Induced Tumor-Derived Exosomes Enhances Metastatic Progression in Head and Neck Cancer. | Head Neck | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Denoising and Baseline Correction of Low-Scan FTIR Spectra: A Benchmark of Deep Learning Models Against Traditional Signal Processing. | Bioengineering (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fusobacterium nucleatum promotes tumor extravasation and metastasis in head and neck cancer via TLR4/MYB/ESPN axis. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Coagulation factor II receptor-like 1 as a prognostic and immuno-modulatory factor in head and neck squamous cell carcinoma. | PeerJ | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An exosome-biomimetic photothermal nanocarrier for IGF2BP2 siRNA delivery and enhanced ferroptosis in head and neck squamous cell carcinoma. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Novel soluble bazedoxifene formulation gains antiproliferative and migrastatic effect in squamous cell carcinoma cells. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RNA sequencing-based evaluation of the mechanisms underlying the liensinine-mediated inhibition of hypopharyngeal cancer proliferation. | J Int Med Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Trim15 stabilizes VDAC3 via ubiquitination to suppress autophagy and enhance chemosensitivity in hypopharyngeal squamous cell carcinoma. | Cell Death Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mutual Exclusion Analysis Shows that DUSP9 Negatively Regulates PD-L1 Expression and Acts as a Target to Enhance Anti-PD-1 Efficacy. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| T2R5 Agonist Phendione Decreases Cell Viability and Induces Apoptosis in Head and Neck Squamous Cell Carcinoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1218/papers